Joerg Moeller, an experienced pharma R&D executive and artificial intelligence (AI) advocate, has been appointed chief executive officer and executive board member of BenevolentAI Ltd. The company applies its AI platform to accelerate drug discovery. Dr Moeller was at Bayer AG for 20 years, culminating in the position of pharmaceutical research and development head of the company’s pharmaceuticals division. His work at Bayer included external strategic AI collaborations. Most recently, Dr Moeller was head of global research and development, at LEO Pharma A/S. He currently is a board member of Secura Bio, a privately held US biotech company.
BenevolentAI announced the appointment on 24 January 2024.
Copyright 2024 Evernow Publishing Ltd